Episode 5: The Changing Treatment Paradigm of HER2+ Metastatic Breast Cancer

HER2+ mBC: Impact of T-DM1 and T-DXd Beyond the Frontline Setting

A discussion focused around shared insight on the roles of trastuzumab emtansine and trastuzumab deruxtecan in relapsed/refractory HER2+ metastatic breast cancer led by Dr. VK Gadi.

The University of Illinois Cancer Center serves as a Strategic Alliance Partner with OncLive. View our complete video library.

Translate »